Leadership & Innovation in Oncology

Board of Directors

Chairman of the Board

Iain Dukes, PhD

Dr. Dukes joined the Iovance Board of Directors and was appointed Chairman of the Board in August 2016. Dr. Dukes is a Venture Partner at OrbiMed Advisors. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research & Development at Amgen. Dr. Dukes has also served as President and Chief Executive Officer, and a member of the Board of Directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Previously, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes serves on the Board of Directors of Themis Biosciences, Ikena Oncology, KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ReViral Limited, and ENYO Therapeutics. Dr. Dukes co-founded and is Chief Executive Officer of Theseus Pharmaceuticals, co-founded and serves on the Board of Directors of Kartos Therapeutics, and co-founded Telios Pharma where he serves as President. Dr. Dukes holds an M.J. and Ph.D. from the University of Oxford, an M.S. in Cardiovascular Studies from the University of Leeds and a B.S. in Pharmacology from the University of Bath.

Director

Ryan Maynard

Mr. Maynard is currently the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked. Mr. Maynard previously was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company. Mr. Maynard has served in various executive roles at Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company, including ten years as Chief Financial Officer. Prior to joining Rigel, Mr. Maynard served as Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, and Controller of General Magic, Inc. Mr. Maynard has held various positions at Siliconix, Inc., including Senior Finance Manager. Mr. Maynard previously worked at Ernst & Young LLP. Mr. Maynard holds a B.S. in Commerce – Accounting from Santa Clara University.

Committees

Audit Committee

Chair

Director

Merrill A. McPeak

General (Ret.) McPeak has extensive leadership experience in the military and as a member of public and private company boards of directors.  He joined the Iovance Board of Directors in July 2011, and served as the interim Chief Executive Officer of Iovance from January 2013 until July 2013. General McPeak currently is the President of McPeak and Associates, a consulting firm that he founded in 1995. General McPeak previously served as a director of several public companies, including Tektronix, Inc., Trans World Airlines, Inc., and ECC International Corp., where he was for many years the chairman of the board. General McPeak has served as a director of Research Solutions, Inc., Aerojet Rocketdyne, Lilis Energy, Valence Surface Technologies, and Navex Global. General McPeak was Chairman of the Board of Coast Plating, Inc., a privately held turnkey provider of metal processing and metal finishing services, from January 2009 until the company was acquired by Trive Capital and renamed Valence Surface Technologies. General McPeak helped found, and served as Chairman of the Board, of EthicsPoint, Inc., a provider of risk management and compliance software-as-a-service that was acquired in 2012 and restyled Navex Global.

From 1990 until his retirement from active military service in late 1994, General McPeak was Chief of Staff of the United States Air Force. As a member of the Joint Chiefs of Staff, General McPeak was a military advisor to the Secretary of Defense and the President of the United States. General McPeak received a Bachelor of Arts degree in economics from San Diego State College and a Master of Science degree in international relations from the George Washington University, and is a member of the Council on Foreign Relations. From July 2010 to December 2017, General McPeak was Chairman of the American Battlefield Monuments Commission.

Committees

Nominating and Corporate Governance Committee

Chair

Audit Committee

Member

Compensation Committee

Member

Director

Wayne Rothbaum

Mr. Rothbaum is currently the President of Quogue Capital LLC, a life sciences investment fund he founded in 2001. Beginning in 2012, Mr. Rothbaum served as the co-founder and largest investor of Acerta Pharma, B.V., a Dutch biotech focused on developing selective, covalent small molecules to treat cancer and inflammation. Acerta Pharma was sold to Astra Zeneca in February 2016. From February 2013 until its sale in February 2016, Mr. Rothbaum served as the executive chairman of Acerta Pharma. From 1993 until 2001, Mr. Rothbaum led the biotechnology practice at the strategic consulting firm The Carson Group. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his Master’s degree in international economics from The George Washington University.

Committees

Compensation Committee

Member

Director

Michael Weiser, MD, PhD

Dr. Weiser is the founder and a principal of Actin Biomed LLC, a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare investment firm. Dr. Weiser currently serves on the Board of Directors of Emisphere Technologies, Inc., a pharmaceutical and drug delivery company. Dr. Weiser previously served as the chairman of the Board of Directors of Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014, and served on the Board of Directors of Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology. Dr. Weiser holds a B.A. in Psychology from the University of Vermont, received his M.D. from New York University School of Medicine and completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College.

Committees

Compensation Committee

Chair

Audit Committee

Member

Nominating and Corporate Governance Committee

Member

Director

Athena Countouriotis, MD

Dr. Countouriotis is the President and Chief Executive Officer, and a member of the Board of Directors of Turning Point Therapeutics. Dr. Countouriotis has also served as the Chief Medical Officer for multiple public biotechnology companies, including Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. Earlier in her career, Dr. Countouriotis led development of products for Pfizer and Bristol-Myers Squibb, including Sutent®, Mylotarg®, Bosulif® and Sprycel®. Dr. Countouriotis also serves on the Board of Directors at Passage Bio. Dr. Countouriotis holds an undergraduate degree from the University of California, Los Angeles and an M.D. from the Tufts University School of Medicine. Dr. Countouriotis received training at the University of California, Los Angeles and at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology-Oncology Program.

Committees

Compensation Committee

Member

Nominating and Corporate Governance Committee

Member